# 1. Financial Performance ## A. Key Figures * **Revenue Growth:** **~17%** QoY (~18% H1) · **~7%** QoY in Indian branded segment * Consolidated EBITDA Margin: **21.68%** Q2 FY'26 (+2.58 ppt YoY) · **~11%** Q2 EBITDA margin from U.S. and Europe * Standalone EBITDA Margin: Improved by 2.57 ppt (from 22.89% to 25.46%) * **Exchange Loss Provision:** **₹10–12 Cr** due to euro volatility * **Gross Margin Trend:** Averaged **54–55%** over last three quarters * **Material Costs:** Down **3–4%** despite revenue growth ## B. Revenue Growth * **Resilient Top-Line Expansion:** Overall business grew ~17% in the quarter amid September headwinds, supported by AI and subsidiaries despite lower-margin profile. * **API-Driven Volatility:** Strong current-quarter API performance includes non-recurring sales, prompting a more conservative full-year growth outlook. * **Currency Drag:** Financial results impacted by **₹10–12 Cr** exchange loss provision due to adverse euro movement, despite operational strength. ## C. EBITDA Margins * **Exceptional Margin Rebound:** Consolidated EBITDA margin surged to 68% from 1% YoY, driven by **Ipca’s turnaround** and elimination of **EUR35–4 Cr annual European facility costs**. * **Profit Mix Enhancement:** Margin expansion fueled by improved product mix in chronic and higher-margin APIs, including bulk procurement by European clients. * **Cost Discipline:** Opex rose only in mid-single digits despite higher R&D, due to tight control on manufacturing overheads and **lower fuel costs** offsetting power inflation. * **Structural Margin Pressure:** Gross margins remain below historical levels due to **loss of high-volume products**, impairing overhead recovery—unrelated to contract manufacturing. ## D. Cash Flow * **Stable Operating Performance:** No major disruptions or additional provisions in Q2, indicating normalized cash generation trends. ## E. Balance Sheet * **Self-Sustaining Liquidity:** No need for cash infusion; company maintains surplus cash, strong operating cash flows, and has fully realized **Jogeshwari land sale proceeds** (closed October). --- # 2. Product & Segment Performance ## A. Key Figures * **API Revenue:** ₹319 Cr → ₹408 Cr Q2 (+28%) * **API Annual Guidance:** 14% full-year growth * **CNS Growth:** 18% Q2 · 14% H1 * **Antibacterial Growth:** 4% Q2 · ~5% H1 * **Derma & Urology Growth:** ~11% each in Q2 * **Domestic Formulations Growth:** ~8% Q2 * **Pain Management Growth:** 10% Q2 · 11% H1 * **Chronic Mix:** 35% of domestic portfolio (↑ from 34%) ## B. API Business * **Robust Regional Momentum:** API business delivered strong double-digit quarterly growth, led by Europe and Latin America, with full-year outlook reaffirmed. * **Segment Recovery:** Cardiovascular segment rebounded after restructuring, showing resilient performance despite initial disruption. * **Mixed Segment Trends:** CNS and Derma/Urology posted strong growth, while antimalarials declined amid broader portfolio realignment. * **Strategic Collaboration:** ANDA synergy framework preserves Unichem’s production rights, enabling coordinated future development based on API availability. * **Improving Associate Performance:** Unichem’s business is recovering post-weak Q1, reducing drag risk for second-half earnings. ## C. Formulation Segments * **Resilient Domestic Growth:** Despite GST-related disruptions in September, domestic formulations rebounded strongly, supported by expanded sales force of **~7,000 medical representatives**. * **Market Share Gains:** Company gained significant domestic share, rising from 3% to 8% over a year, while maintaining rank at ~16 (IQVIA MAT). * **Pain Management Strength:** Flagship segment continues on a stable growth trajectory, underpinned by the Flexicare expansion despite current losses. * **Operational Headwinds:** Lyka Labs faced severe P2P model disruption due to customer deferrals ahead of GST changes, impacting near-term performance. * **Selective Pressure:** Muted growth in one product is isolated and not affecting overall margin profile, with other products delivering healthier returns. ## D. Chronic vs Acute Mix * **Strategic Shift Confirmed:** Chronic therapy share rose to 35%, signaling continued pivot toward higher-value, stickier chronic care despite market chronic share at 40%. ## E. Branded vs Generic * **Stable H2 Outlook:** Generic formulations expected to grow 8–9% in second half, reflecting recovery from earlier disruptions. * **Branded Export Resilience:** Despite ROW volatility and Q2 softness, full-year branded export growth forecast remains strong at 9–10%. --- # 3. Geography & Market Mix ## A. Key Figures * **B. S. Revenue (H1):** **₹55 Cr** * **Export Formulation Revenue (Q2 FY26):** **₹493 Cr** (–9% YoY) · **H1 FY26:** **₹941 Cr** (vs. ₹937 Cr prior year) ## B. U.S. Contribution * **Strong U.S. Momentum:** U.S. operations are a key growth engine, with robust execution reflected in six product shipments and a deep pipeline of **five to six products in manufacturing**. * **High U.S. Exposure:** Unichem’s business is highly concentrated in the U.S., now representing **~70% of operations**, above prior guidance, supported by integrated API supply and a three-month inventory buffer. * **Market Share Upside:** Company expects to capture **~25% of U.S. partner’s sales** under current agreement, signaling incremental revenue potential. * **Gradual Geographic Diversification:** U.S. contribution is expected to **moderately decline over 3–5 years** as new geographies scale, though growth will remain steady and sequential. ## C. Domestic & European Trends * **Domestic Growth Normalizing:** India business continues to outperform market trends but at a more moderate pace, with **slightly above-market growth** amid broader deceleration and upcoming GLP-driven opportunities. * **Europe: Strong Market, Soft Execution:** Despite Europe being a high-performing region for peers, company’s export growth has lagged due to temporary underperformance in shipments. ## D. ROW & Export Formulations * **Export Formulations Stalled:** International formulation sales declined **~9% YoY in Q2**, resulting in flat H1 performance despite recovery in non-core markets. * **Rebound in Non-U.S. Exports:** Generics exports are expected to grow **8–9% in H2**, driven by restocking and recovery outside a previously disrupted product line. --- # 4. R&D & Pipeline Progress ## A. Key Figures * R&D Spend: 3.91% of turnover in Q2 FY'26 (vs. 2.7% Q2 FY'25) · Expected to stabilize at ~4% of turnover for FY'26 * **Pipeline Filing Capacity:** **30–35 products** across markets (each market filing counted separately) * **Regulatory Timelines:** **12–18 months** per market for registration in Europe, Australia, NZ, Canada · **1–5 years** for broader market approvals * Future R&D Guidance: Projected to rise to 4.5–4.75% of turnover next year due to biosimilar clinical trials ## B. Dossier Filings & Pipeline Strategy * **Global Expansion Underway:** Active dossier filings in Europe, Australia, NZ, Canada, and other regions, with robust pipeline momentum and **no overlap in R&D efforts** post-merger. * **C. S. Focus Shifts In-House:** Future U.S. filings will be limited to **internally developed products**, excluding third-party API-based submissions, signaling strategic control over quality and supply. * **Cross-Selling Still Nascent:** Only **two dossiers registered** to date; commercial synergies remain in early stages despite pipeline progress. ## C. Biosimilar Development * **Biosimilars Drive Future Spend:** R&D investment set to rise meaningfully next year as **three of seven biosimilar projects** enter clinical trials, supported by an experienced global partner. * **API Self-Reliance Prioritized:** Internal API development underway to reduce third-party dependency, though pace will be selective based on cost and market dynamics. ## D. GLP-1 Preparedness * **Late-Mover Strategy in GLP-1:** No current capability for *E. coli*-based GLP-1 development; building dedicated biotech R&D facility to target **next phase entry**, not current market wave. * **Foundational Work Advancing:** Preliminary clone synthesis and R&D setup in progress, positioning for future participation in high-growth metabolic therapies. ## E. Internal R&D Capacity * **Strategic Pipeline Building:** Focus on leveraging --- # 5. Manufacturing & Supply Chain ## A. Facility Transfers * **European Operations Consolidated:** Full transfer of European facility operations to Unichem’s **Baddi site**, now fully approved and customer-cleared. * **Ireland Site Closure Underway:** Wind-down of Ireland facility completed, with associated costs recognized in Q1; marks strategic consolidation. * **Biosimilar Tech Transfer Monetized:** Successful deal with Puerto Rico-based partner for legacy biosimilar, including **full drug substance and product technology transfer**. * **Regulatory Leverage via Partnership:** Collaboration expected to accelerate **B. S. FDA and global market qualification** of manufacturing assets through partner’s regulatory consulting expertise. * **Commercial Division of Labor:** Partner to target **government tenders**, while company focuses on **private-sector sales** and joint **clinical trial participation**. ## B. API Sourcing * **Cost Optimization Completed:** Unichem finalized prior-year initiatives in logistics, shipping, and energy, contributing to structural cost reduction. * **Ipca-Sourced APIs Pending Launch:** Regulatory submission complete for Ipca APIs at Unichem, but supply delayed by **six to nine months** pending final approvals. * **Internal API Supply to Ramp Next FY:** Major API supply from company to Unichem set to begin **next financial year** post-clearance. * **Selective API Outsourcing Strategy:** Development capacity for **five to six APIs** in-house; outsourcing planned for low-cost or commoditized APIs. ## C. Inventory Strategy * **Inventory Disparity Noted:** Unichem maintains **significantly higher inventory levels** than Ipca despite operational similarities; no explanation provided. * **Renewables Driving Savings:** Renewable power projects delivering **1% cost savings** from reduced energy expenses. ## D. Regulatory Approvals * **Dual Facility Approvals Expected:** Both partners’ sites on track for regulatory greenlight, enabling expanded market access and joint commercialization. --- # 6. Pricing & Competitive Risks ## A. Market Share Shifts * **Mixed Share Dynamics:** Unichem has lost share in certain products due to aggressive competitor pricing but gained in others, with revenue realization expected to lag. * **Recovery Outlook:** Market share volatility is inherent in generics; lost positions are viewed as recoverable in future tender cycles despite non-tender-based model. ## B. Price Erosion * **Margin Pressure:** Q1 margins weighed down by European restructuring, including **closure of a manufacturing facility**, and ongoing U.S. pricing pressures. * **Sustained Price Erosion:** U.S. generic price declines expected at **lower single-digit rates**, in line with sector trends, driven by competitive intensity. * **Pricing Volatility:** Prices fluctuate dynamically by product based on competition levels—**increased rivalry drives cuts**, while **reduced competition may enable increases**—amid a current environment of **no supply shortages** limiting margin-boosting opportunities. --- # 7. Guidance & Outlook ## A. Key Figures * **India Revenue Growth Guidance:** **10% to 11%** (maintained) · **8% to 10%** (adjusted for product share losses) * **Consolidated Margin Guidance:** **>20%** expected in H2 FY (up **~100 bps** from prior guidance) ## B. Full-Year Revenue * **Resilient Growth Trajectory:** Maintains 10–11% India growth outlook despite near-term headwinds, with slightly lower overall growth due to market share losses in key products. * **No Near-Term Monetization:** Deal-related revenues will not contribute in current financial year, aligning with conservative revenue recognition. ## C. Margin Forecast * **Upgraded Margin Outlook:** Reversed prior contraction forecast, now expecting **~100 bps improvement** driven by favorable product mix and strong Q2 execution. * **Stability Ahead of Expansion:** Margins to remain range-bound near current levels until regulatory approvals unlock incremental upside from new markets. * **Long-Term Margin Maturation:** Potential to reach **15–20%** range over **2 to 5 years** as synergies and dossier approvals are fully realized. ## D. Strategic Expansion * **New Verticals in Development:** Expanding into **cosmetic dermatology** and **pain management** (Flexicare) to leverage core orthopedic strengths and diversify revenue base. * **Multi-Year Market Rollout:** Full commercial expansion expected over **2–3 years** post-regulatory clearance, with confidence in outpacing market growth via GLP opportunity and domestic reach.